Abstract
Background:
Epilepsy is a multifactorial disease characterized by spontaneous, recurrent seizures and a growing incidence of comorbid conditions such as anxiety, depression, cognitive dysfunction, and sudden unexpected death. Patients with epilepsy often experience cognitive impairment or dysfunction that can negatively affect their quality of life. There is limited research on cognitive dysfunction assessed through the Montreal Cognitive Assessment (MoCA) in the Amhara region, although the MoCA is considered superior to the Mini-Mental State Examination (MMSE). Therefore, this study aimed to assess cognitive dysfunction and identify factors associated with it in patients with epilepsy who were receiving follow-up care at referral hospitals in the Amhara region.
Materials and methods:
A multicenter, institutional-based cross-sectional study was conducted among patients with epilepsy who were receiving follow-up care at randomly selected referral hospitals in the Amhara region from January 2024 to July 2024. A total of 355 participants were recruited for the study using a systematic random sampling technique, achieving a response rate of 98%. Cognitive dysfunction was measured using the MoCA. Data were entered with EpiData version 4.7 and then exported into SPSS version 26 for analysis. Multivariable logistic regression analysis was conducted, and a p-value of ≤0.05 was considered statistically significant. The results are presented in text and tables.
Results:
The majority of the participants were women (52.1%). The mean age of the study participants was 31 (± 5.4) years. The prevalence of cognitive dysfunction was 29% (95% CI: 25.8, 34.5). Multivariable logistic regression analysis revealed that several factors were statistically significantly associated with cognitive dysfunction. Factors associated with cognitive dysfunction included being a rural resident (adjusted odds ratios (AOR) = 1.21; 95% CI: 1.29, 1.43), having a medical illness (AOR = 2.5; 95% CI: 2.1, 9.1), experiencing generalized seizures (AOR = 1.3; 95% CI: 1.08, 3.1), having a seizure frequency of daily to every other day (AOR = 2; 95% CI: 1.5, 9.2), experiencing seizures for more than 30 years (AOR = 1.5; 95% CI: 1.7, 7.6), and using a combination of anti-seizure drugs (AOR = 2.5; 95% CI: 1.2, 6.2).
Conclusions and recommendations:
In this study, a significant proportion of patients with epilepsy receiving follow-up care experienced cognitive dysfunction. Neuropsychological assessment should be emphasized in patients with epilepsy at diagnosis and early follow-up phases of the condition.
Introduction
Epilepsy is a multifactorial disease characterized by spontaneous, recurrent seizures and a growing incidence of comorbid conditions such as anxiety, depression, cognitive dysfunction, and sudden unexpected death (1–3). It has a devastating effect on the social, cognitive, psychological, and physical aspects of life, ultimately affecting the quality of life of the patients (4, 5). Epilepsy is the most common serious chronic neurological condition, affecting 7.6 individuals per 1,000 globally across all ages, sexes, ethnicities, and social statuses, regardless of the geographic location (6). Notably, its incidence and prevalence are slightly higher in men than in women and are also higher in developing countries (7, 8).
A study conducted in Australia showed that patients experiencing epileptic seizures performed more poorly in executive function, language, and memory areas compared to those with non-epileptic seizures. Several risk factors are likely involved in the development and progression of cognitive dysfunction in patients with epilepsy (9, 10). Generalized tonic–clonic status epilepticus is one of the risk factors for cognitive dysfunction (9, 11). Other factors include the underlying etiology, recurrent seizures, structural damage that leads to secondary epilepsy, genetic variants, and molecular changes (5, 12). A study showed that anti-seizure drugs were not independently associated with cognitive function (11). Physiological causes of cognitive dysfunction associated with epilepsy include disruptions in GABAergic transmission and/or function, and abnormal presence of excitatory loops (5, 13). As a consequence of these deficits, the temporal organization of neuronal firing within networks and across structures is altered, leading to a progressive decline in cognitive function (1, 14). Therefore, restoring these circuits may help prevent seizures and cognitive deficits (3, 15, 16). The impact of epilepsy on cognition has both transient and prolonged effects, such as functional and structural abnormalities. Comorbidity with cognitive dysfunction worsens the situation (2, 3, 17).
The prevalence and incidence of epilepsy in Ethiopia are high, affecting 29.5 per 1,000 population, with an annual incidence of 64 per 100,000 inhabitants (18, 19). In countries like Ethiopia, where many individuals have limited awareness of health concerns, a significant proportion of the population seeks medical help from traditional healers for their ailments, and traditional medicine is commonly utilized. The cultural acceptance of these healers, the affordability of traditional remedies, and the challenges of accessing modern healthcare services contribute to the reliance on traditional medicine by up to 80% of individuals in developing countries (20). The occurrence of uncontrolled seizures was observed to be higher than the anticipated frequency, which ideally should be zero after 1 year of treatment. Factors related to clinical conditions and treatment have been identified as contributing to the occurrence of uncontrolled seizures (21).
Patients with epilepsy experience significant cognitive impairment that is influenced by various epilepsy-related characteristics (22). Comorbid cognitive impairment can negatively impact the quality of life of individuals with epilepsy (23, 24). However, this impairment often does not receive adequate attention and are frequently left untreated. Studies conducted in Zambia, East Gojam hospitals, and the University of Gondar Specialized Hospital have shown that nearly half of the study participants with epilepsy experienced impaired quality of life (6, 9, 25, 26). A notable incidence of cognitive impairment or dysfunction has been observed in treatment-naïve individuals with epilepsy, significantly affecting their memory, mental processing speed, and language abilities (27). Patients with epilepsy also experience sleep disturbances that contribute to cognitive dysfunction (28).
The prevalence of cognitive impairment in health institutions in Gurage Zone and South Gondar of Ethiopia was reported to be 25.6 and 69.2%, respectively (29, 30). Studies on cognitive dysfunction using the Montreal Cognitive Assessment (MoCA)—a useful tool for assessing cognition in low-to-middle-income countries, where neuropsychological tools are limited—among patients with epilepsy in the Amhara region are scarce. We aimed to assess cognitive dysfunction and identify factors associated with it in patients with epilepsy who were receiving follow-up care at referral hospitals in the Amhara region. This study may be used as a resource for clinicians emphasizing cognitive dysfunction in the treatment and follow-up of patients with epilepsy and as a baseline for researchers conducting further studies.
Materials and methods
Study area, study period, and study design
A multicenter, institutional-based cross-sectional study was conducted in referral hospitals in the Amhara region from January 2024 to July 2024. The Amhara region is one of the largest regions in Ethiopia. Bahir Dar is the capital of the Amhara region, which is approximately 500 km away from the capital of Ethiopia, Addis Ababa. There are eight referral hospitals in the region. This study was conducted in three randomly selected referral hospitals, each serving between 5 and 7 million people.
Population and sample size calculation
The source population consisted of patients with epilepsy aged 18 years or older who were undergoing follow-up at referral hospitals in the Amhara region. The study population included those patients with epilepsy, aged 18 years or older, who were undergoing follow-up and were present during the data collection period.
Using the single proportion population formula, the sample size was determined based on the estimated prevalence of cognitive dysfunction, which was 69.2%, as identified in a study conducted in South Gondar (23). Since South Gondar is located in the Amhara region, the study participants shared similar sociodemographic and behavioral characteristics, disease burden, and access to healthcare as those in our study.
After adding a non-response rate of 10%, the total sample size was calculated to be 362, with a 5% margin of error and a 95% confidence interval.
Sampling technique and procedure
Of the eight referral hospitals, three were selected using the lottery method.
Study participants were recruited using a systematic random sampling technique. First, a list of patients was created for each randomly selected health institution. Proportional allocation was applied to the selected referral hospitals. Finally, the study population was selected through systematic random sampling (refer to Figure 1).
Figure 1
Sampling procedure for the assessment of cognitive dysfunction in epileptic patients at referral hospitals in the Amhara region, 2024.
Eligibility criteria
Inclusion criteria
All adult epileptic patients aged 18 years and older who were undergoing follow-up at the selected referral hospitals were included in the study.
Exclusion criteria
Epileptic patients who were severely ill and those with observable verbal communication problems were excluded from the study.
Study variables
The dependent variable was cognitive impairment measured using the MoCA as a dichotomous variable (Yes/No).
Independent variables were as follows: sociodemographic factors (age, sex, residence, marital status, occupation, income, and educational status); behavioral and clinical variables (substance use and medical illness); seizure-related factors (seizure frequency, duration of seizures, and type of seizures); and medication-related factors (anti-seizure drugs, frequency of medication, and comfort with medications). Comfort with medications was assessed by directly asking the study participants about their experience and elaborating on the side effects of the drugs. If the patient reported no side effects, they were considered to be comfortable with the medication, and if the patient experienced side effects, they were considered to be uncomfortable.
Data collection tools
Data were collected through in-person interviews using an Amharic adaptation of a standardized questionnaire. Cognitive dysfunction was assessed using the MoCA, which is a sensitive and rapid assessment tool for screening patients with cognitive dysfunction. The cognitive domains assessed included visuospatial/executive, naming, attention, language, abstraction, orientation, and delayed recall. The total score was 30 points, with a score of 26 or above indicating normal cognitive function. An additional point was added for the participants with less than 12 years of education.
Cognitive dysfunction: A patient was considered to have cognitive dysfunction when their MoCA score was less than 26 (31). One point was added for the participants with less than 12 years of education.
Medical illness: To assess the history of medical illness, the respondents were asked, “Did you have any medical illness (e.g., DM, HTN, HIV/AIDS, etc.)?” The responses were recorded as yes/no.
Substance use: This included consumption of cigarettes, alcohol, or khat (9).
Data quality control
A total of 12 BSc-level psychiatry professionals, 4 from each of the three participating hospitals, were selected and appointed as data collectors. Training was provided to both data collectors and supervisors on proper data collection techniques. The questionnaire was translated into Amharic and translated back into English to ensure consistency. Two weeks prior to data collection, a pretest was conducted on 5% (15) of the samples from Bahirdar Felege Hiwot Referral Hospital to assess the clarity of instruments. The data from the pretest were excluded from the main analysis. Based on the pretest findings, the questionnaire—particularly the structured portion—was revised and adapted. The participants gave informed consent after receiving the study information. Regular supervision was provided during the data collection, and daily checks were conducted to ensure data completeness and consistency.
Data entry, processing, and analysis
The data were initially entered into EpiData version 4.7 and then exported to SPSS version 26 for statistical analysis. Descriptive results were presented using frequency tables and text. Bivariate analysis was performed to explore the association between the predictor and dependent variables, and a p-value of less than or equal to 0.25 was used as the cutoff for multivariable logistic regression. To control for confounding factors and identify the most significant variables, multivariable logistic regression analysis was conducted. The strength of the association was measured using an adjusted odds ratio (AOR) with a 95% confidence interval, and a p-value of less than 0.05 was considered statistically significant. The model fit was assessed using the Hosmer–Lemeshow test (p = 0.32). Multicollinearity among the independent variables was assessed using the variance inflation factor (VIF) and tolerance. VIF values were less than 10, while tolerance values were greater than 0.1, indicating no dependence among the independent variables.
Ethical clearance
Ethical clearance was obtained from the Institutional Review Committee of the University of Gondar, and written permission was secured from each participating hospital. All participants provided written informed consent, and confidentiality was maintained by removing personal identifiers. The study’s purpose, benefits, and voluntary nature were explained, emphasizing the participant’s right to withdraw at any time. While no direct benefits were offered, the participants identified with cognitive dysfunction through the MoCA were referred to specialists or psychiatrists for timely and appropriate interventions, such as non-pharmacological treatments such as cognitive rehabilitation, cognitive training, and memory aids.
Results
Sociodemographic characteristics of the study participants
In this study, a total of 355 participants were included, achieving a response rate of 98%. The majority of the participants were women (53.8%). The mean age of the study participants was 31 years (±5.4). Approximately 44.2% of the participants were single, and 30.4% of the study participants had no formal education. The majority (58.9%) of the participants resided in rural areas, and approximately 52.4% were farmers. A total of 38.6% of the participants reported a monthly income ranging from 1,000 to 2000 ETB (see Table 1).
Table 1
| Study variables | Category | Frequency | Percentage |
|---|---|---|---|
| Sex | Male subjects | 164 | 46.2 |
| Female subjects | 191 | 53.8 | |
| Age | 18–25 | 80 | 22.5 |
| 26–35 | 115 | 32.4 | |
| 36–45 | 141 | 39.7 | |
| >45 | 19 | 5.4 | |
| Marital status | Single | 157 | 44.2 |
| Married | 156 | 43.9 | |
| Divorced | 32 | 9 | |
| Widowed | 9 | 2.5 | |
| Residence | Urban | 146 | 41.1 |
| Rural | 209 | 58.9 | |
| Level of education | No formal education | 108 | 30.4 |
| Primary education (1-8) | 110 | 31 | |
| Secondary education (9-12) | 100 | 28.1 | |
| Diploma and above | 37 | 10.4 | |
| Occupation | Government employee | 119 | 33.5 |
| Farmer | 186 | 52.4 | |
| NGO | 10 | 2.8 | |
| Others/unemployed | 40 | 11.3 | |
| Income | ≤1,000 | 94 | 26.5 |
| 1,001–2000 | 137 | 38.6 | |
| 20,001–3,500 | 74 | 20.8 | |
| >3,500 | 50 | 14 |
Sociodemographic characteristics of the patients with epilepsy who were undergoing follow-up at the randomly selected referral hospitals in the Amhara region, 2024.
Behavioral and clinical characteristics of the study participants
In the present study, 49% of the study participants had a history of substance use. A total of 50.1% were diagnosed with generalized tonic–clonic seizures, and 21.1% had a history of medical illness. Approximately 27% of the study participants experienced seizures daily or every other day. Of the participants, 35% used phenobarbitone. The majority of the study participants (51.3%) took their medication twice daily, and 51.3% were comfortable with their medication. The overall prevalence of cognitive dysfunction based on the MoCA was 29% (See Table 2).
Table 2
| Study variables | Category | Frequency | Percentage |
|---|---|---|---|
| Substance use | Yes | 174 | 49 |
| No | 181 | 51 | |
| Medical illness | Yes | 75 | 21.1 |
| No | 280 | 78.9 | |
| Type of seizure | Generalized seizures | 178 | 50.1 |
| Focal seizures | 177 | 49.9 | |
| Frequency of seizure | Daily to every other day | 95 | 26.8 |
| Weekly to every other week | 99 | 27.9 | |
| Once in 3–4 weeks | 95 | 26.8 | |
| Once in the past 1–6 months | 34 | 9.6 | |
| 6–11 months ago | 23 | 6.5 | |
| 1–4 years ago | 19 | 5.4 | |
| Duration of seizure (years) | ≤10 | 118 | 33.2 |
| 11–20 | 141 | 39.7 | |
| 21–30 | 66 | 18.6 | |
| >30 (36) | 31 | 8.7 | |
| Anti-seizure drugs | Phenytoin | 124 | 35 |
| Phenobarbitone | 113 | 31.8 | |
| Valproate | 48 | 13.5 | |
| Combination | 70 | 19.7 | |
| Frequency of medication | Once daily | 173 | 48.7 |
| Twice daily | 182 | 51.3 | |
| Comfortable with medication | Yes | 173 | 48.7 |
| No | 182 | 51.3 | |
| Cognitive dysfunction | Yes | 103 | 29 |
| No | 252 | 71 |
Behavioral and clinical characteristics of the patients with epilepsy at the randomly selected referral hospitals in the Amhara region, 2024.
Prevalence of cognitive dysfunction (CD)
In this study, 29% of the study participants (103 out of 355) had cognitive dysfunction (95% CI; 25.8, 34.5), with a MoCA score below 26. The mean MoCA score for patients with epilepsy who were undergoing follow-up was 27.74 (SD ± 1.76), with minimum and maximum values of 23 and 30, respectively. See Table 3 for details of the measurements of cognitive dysfunction.
Table 3
| Components of the MoCA | Maximum normal value | Minimum | Maximum | Mean | SD |
|---|---|---|---|---|---|
| Visuospatial/executive | 5 | 3 | 5 | 4.87 | ±0.34 |
| Naming | 3 | 2 | 3 | 2.98 | ±0.1 |
| Attention | 6 | 3 | 6 | 5 | ±0.73 |
| Language | 3 | 2 | 3 | 2.96 | ±0.17 |
| Orientation | 6 | 3 | 6 | 5.1 | ±0.71 |
| Abstraction | 2 | 1 | 2 | 1.98 | ±0.1 |
| Delayed recall | 5 | 3 | 5 | 4.71 | ±0.49 |
| Total | 30 | ||||
Values of the measurements of cognitive dysfunction based on the MoCA.
Factors associated with cognitive dysfunction in patients with epilepsy
Bivariable and multivariable logistic regression analyses of cognitive dysfunction were conducted, as detailed in Table 3. In the bivariable analysis, age, residence, educational status, substance use, medical illness, type of seizure, frequency of seizure, duration of seizure, anti-seizure drugs, and frequency of medication were considered candidate variables for the multivariable analysis (p ≤ 0.25). The multivariable logistic regression analysis revealed statistically significant factors associated with cognitive dysfunction, such as residence (AOR = 1.21; 95% CI: 1.29, 4.43), medical illness (AOR = 2.5; 95% CI: 2.1, 9.1), generalized seizure (AOR = 1.3; 95% CI: 1.08, 3.1), seizures occurring daily to every other day (AOR = 2; 95% CI:1.5, 9.2), seizure duration greater than 30 years (AOR = 1.5; 95% CI: 1.7, 7.6), and a combination of anti-seizure drugs (AOR = 2.5; 95% CI: 1.2, 6.2) (Table 4).
Table 4
| Variables | Category | CD | COR (95% CI) | AOR (95% CI) | p-value | |
|---|---|---|---|---|---|---|
| Yes N (%) | No N (%) | |||||
| Sex | Male subjects | 54 (15.2) | 110 (31) | 1 | ||
| Female subjects | 49 (13.8) | 142 (40) | 1.4 (0.75, 1.68) | |||
| Age | 18–25 | 22 (6.2) | 58 (16.3) | 1 | 1 | 1 |
| 26–35 | 24 (6.7) | 91 (25.6) | 2.4 (2.9, 20.1) | 1.13 (0.8, 22) | 0.15 | |
| 36–45 | 51 (14.3) | 90 (25.3) | 3.1 (2.6, 13.7) | 1.5 (0.1, 9.5) | 0.08 | |
| >45 | 6 (1.3) | 13 (3.6) | 4.4 (1.8, 15) | 3.2 (0.98, 12) | 0.06 | |
| Marital status | Single | 45 (12.7) | 112 (31.5) | 1 | ||
| Married | 43 (12.1) | 114 (32.1) | 1.2 (0.7, 5) | |||
| Divorced | 12 (3.4) | 20 (5.6) | 1.4 (0.811) | |||
| Widowed | 3 (0.8) | 6 (1.3) | 1.6 (0.413) | |||
| Residence | Urban | 47 (13.2) | 99 (27.8) | 1 | 1 | 1 |
| Rural | 56 (15.8) | 153 (43) | 1.29 (1.53, 1.79) | 1.21 (1.29, 1.43)* | 0.003 | |
| Level of education | No formal education | 35 (9.8) | 73 (20.5) | 1.5 (0.6, 12.4) | 1.7 (0.2, 1.03) | 0.064 |
| Elementary school | 26 (7.3) | 84 (23.7) | 1.4 (0.4, 9.7) | 1.6 (0.3, 1.67) | 0.32 | |
| Secondary school | 32 (9) | 68 (19.1) | 1.3 (0.5, 4.9) | 1.4 (0.1, 1.2) | 0.41 | |
| Diploma and above | 10 (2.8) | 27 (7.6) | 1 | 1 | 1 | |
| Occupation | Government employee | 37 (10.4) | 82 (23) | 1 | ||
| Farmer | 52 (14.6) | 134 (37.7) | 1.5 (0.2, 1.8) | |||
| NGO | 2 (0.5) | 8 (2.2) | 1.3 (0.5, 3.4) | |||
| Others/unemployed | 12 (3.3) | 28 (7.9) | 1.6 (0.9, 7.2) | |||
| Income | ≤ 1,000 | 32 (9) | 62 (17.4) | 2 (0.6, 5.3) | ||
| 1,001–2000 | 43 (12.1) | 94 (26.4) | 1.5 (0.4, 3) | |||
| 2001–3,500 | 23 (6.5) | 51 (14.3) | 1.4 (0. 23, 9) | |||
| >3,500 | 5 (1.4) | 45 (12.7) | 1 | |||
| Substance use | Yes | 58 (16.3) | 116 (32.7) | 1.51 (1.1, 4.2) | 1.6 (0.9, 5.6) | 0.062 |
| No | 45 (12.7) | 136 (38.3) | 1 | 1 | 1 | |
| Medical illness | Yes | 37 (10.4) | 38 (10.7) | 3.1 (2.3, 10.7) | 2.5 (2.1, 9.1) | 0.002 |
| No | 66 (18.6) | 214 (60.3) | 1 | 1 | 1 | |
| Type of seizure | Generalized | 60 (16.9) | 118 (33.2) | 1.62 (1.1, 2.58) | 1.3 (1.08, 3.1)* | 0.01 |
| Focal | 42 (11.8) | 134 (37.7) | 1 | 1 | 1 | |
| Frequency of seizure | Daily to every other day | 37 (10.4) | 58 (16.3) | 1.81 (1.3, 12) | 2 (1.5, 9.2)* | 0.047 |
| Weekly/every other week | 27 (7.6) | 72 (20.3) | 2.1 (1.8, 9.7) | 1.9 (1.2, 11) | 0.06 | |
| Once in 3–4 weeks | 19 (5.4) | 76 (21.4) | 2.3 (1.6. 9.1) | 1.2 (1.62, 10) | 0.19 | |
| Once in the past 1–6 months | 10 (2.8) | 24 (6.8) | 1.2 (1.5. 8.5) | 1.1 (1.3, 9.4) | 0.23 | |
| 6–11 months ago | 6 (1.7) | 17 (4.8) | 1.9 (1.1, 13) | 1.6 (1.09, 14) | 0.15 | |
| 1–4 years ago | 4 (1.1) | 15 (4.2) | 1 | 1 | 1 | |
| Duration of seizure (years) | ≤ 10 | 37 (10.4) | 81 (22.8) | 1 | 1 | 1 |
| 11–20 | 48 (13.5) | 93 (26.2) | 2.4 (1.1, 4.6) | 1.8 (0.5, 5.4) | 0.21 | |
| 21–30 | 10 (2.8) | 56 (15.8) | 1.53 (0.9, 12.1) | 1.46 (0.3, 13) | 0.25 | |
| >30 | 9 (2.5) | 22 (6.2) | 1.6 (2.1, 5.3) | 1.5 (1.7, 7.6)* | 0.04 | |
| Anti-seizure drugs | Phenytoin | 43 (12.1) | 81 (22.8) | 1 | 1 | 1 |
| Phenobarbitone | 35 (9.9) | 78 (21.9) | 1.9 (1.64, 2.7) | 1.7 (0.52, 6.6) | 0.06 | |
| Valproate | 11 (3.10) | 37 (10.4) | 1.4 (1.84, 3.45) | 1.2 (0.9, 5.4) | 0.07 | |
| Combination | 14 (3.9) | 56 (15.8) | 3.1 (1.3, 5.6) | 2.5 (1.2, 6.2)** | 0.001 | |
| Frequency of drugs | Once daily | 61 (17.2) | 112 (31.5) | 1 | 1 | 1 |
| Twice daily | 42 (11.8) | 140 (39.4) | 1.8 (1.07, 7.8) | 1.4 (0.8, 8.2) | 0.052 | |
| Comfortable with drug | Yes | 54 (15.2) | 118 (33.3) | 1 | 1 | 1 |
| No | 49 (13.8) | 132 (37.1) | 1.23 (1.08, 9.5) | 1.3 (0.9, 8.4) | 0.14 | |
Factors associated with cognitive dysfunction in patients with epilepsy in the randomly selected referral hospitals in the Amhara region, 2024.
1, reference category, Hosmer–Lemeshow value = 0.32; *, p ≤ 0.05; **, p ≤ 0.001. Bold values indicate associated factors to the dependent variable.
Discussion
The present study identified the prevalence of cognitive dysfunction and its associated factors in patients with epilepsy. The observed prevalence of cognitive dysfunction in patients with epilepsy undergoing follow-up at the three randomly selected referral hospitals in the Amhara region was determined to be 29% (95% CI; 25.8, 34.5). This rate is comparable to studies conducted in the Gurage zone at 25.6% (29) and in Burkina Faso at 25.5% (32). This slight variation may be due to differences in the measurement of cognitive dysfunction, as these studies used the Mini-Mental State Examination (MMSE), which measures mild cognitive dysfunction. This implies that, despite a normal MMSE score, the MoCA could be used to detect cognitive dysfunction (31). On the other hand, the prevalence of cognitive dysfunction in our study was lower than that reported in a study conducted in South Gondar health institutions, where the prevalence was 69.2% (33). This variation could be due to differences in the study area, as the previous study focused on patients with epilepsy who had follow-ups in primary hospitals, which may not have sufficient resources (such as physicians and laboratory facilities) to diagnose epilepsy, compared to referral hospitals. The prevalence of cognitive dysfunction in our study was also lower than that in a study conducted in the United States, which was 60% (34). This variation may be due to differences in the study area, study design, sample size, and measurement of cognitive dysfunction.
Rural residents were twice as likely to have cognitive dysfunction compared to urban residents. This finding is supported by studies conducted in Ethiopia (33) and Burkina Faso (32). A possible reason may be that rural residents have limited access to early diagnosis, treatment, or follow-up and they may prefer to visit holy water sites or mosques, which may result in diagnostic delays and complicate the nature of the seizures (35). All of these factors may lead to cognitive dysfunction.
The patients with epilepsy who had comorbid medical illnesses were 2.5 times as likely to experience cognitive dysfunction compared to those who did not have comorbid medical illnesses. This result is in line with findings from studies conducted in the United States (34), Spain (36), Slovakia (37), and South Korea (38). This may be explained by medical illnesses such as hypertension and DM, which can cause memory loss and poor executive function (38).
The type of seizure (generalized seizures) was associated with cognitive dysfunction. The patients with epilepsy who had generalized seizures were 1.6 times more likely to have cognitive dysfunction compared to those who had focal seizures. This result is in line with findings from studies conducted in Ethiopia (29), China (39), the United States (35), Australia (17) Slovakia (37), Spain (36), and Norway (12). This may be explained by the fact that alterations in neuronal dynamics are more common in generalized seizures than in focal seizures, resulting in reduced abilities in various executive functions and the acquisition of knowledge (3, 36). The relationship between cognitive impairment and seizure characteristics is frequently perceived as one in which changes in seizure characteristics lead to changes in cognitive ability (40).
The frequency of seizures and the duration of seizures were also associated with cognitive dysfunction. This finding is supported by studies conducted in Slovenia (7), Australia (11), The Netherlands (41), the United States (35), and Egypt (22). This may be explained by alterations in the glutamate–glutamine cycle components, such as neurotransmitters and metabolites, enzymes, amino acid transporters, and glutamate receptors (1). Changes in neural networks may increase the risk of seizures and related cognitive impairment (42).
Patients taking a combination of anti-seizure drugs were 2.5 times more likely to experience cognitive dysfunction compared to those taking monotherapy. This result is in line with findings from studies conducted in Thailand (31), Australia (11), China (39), and Slovenia (7). This may be explained by the effects of a combination of anti-seizure drugs that affect memory and concentration (phenobarbitone), attention, problem-solving, and visuomotor tasks (phenytoin) (35).
Conclusions and recommendations
The results of this study showed that a significant proportion of patients with epilepsy had cognitive dysfunction. Factors such as residence, medical illness, type of seizures, frequency of seizures, duration of seizures, and a combination of anti-seizure drugs were associated with cognitive dysfunction. Emphasis should be given to patients with epilepsy, especially to those who are rural residents, have another medical illness, experience generalized seizures, have seizures occurring daily or every other day, have had seizures for more than 30 years, and have used a combination of anti-seizure drugs. Health education, regular neuropsychological assessments, and early screening for the side effects of anti-seizure drugs should be implemented to raise awareness of cognitive dysfunction at an early stage.
Strengths and limitations of the study
The strength of this study is that it was conducted in referral hospitals, where the diagnosis of epilepsy is more accurate due to the presence of experienced physicians, neurologists, and other laboratory setups, such as CT scans or MRI facilities. Recognizing cognitive dysfunction allows healthcare providers to develop more individualized treatment plans, ultimately improving the quality of life of the patients. This study has some limitations. First, since our tool was the MoCa, it may have been less sensitive in populations with high educational attainment. In some cases, individuals without cognitive impairment may have scored below the cutoff, leading to false positives. Second, we did not perform electroencephalograms (EEGs) or organ function tests. Finally, there may be a risk of recall bias.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by Institutional review committee of University of Gondar. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
LM: Conceptualization, Methodology, Project administration, Software, Supervision, Writing – original draft, Writing – review & editing. YG: Data curation, Investigation, Validation, Writing – original draft, Writing – review & editing. MG: Software, Supervision, Writing – original draft, Writing – review & editing. DAd: Formal analysis, Supervision, Writing – original draft, Writing – review & editing. DAn: Data curation, Formal analysis, Writing – original draft, Writing – review & editing. ET: Resources, Visualization, Writing – original draft, Writing – review & editing. HA: Conceptualization, Data curation, Writing – original draft, Writing – review & editing. AB: Methodology, Supervision, Writing – original draft, Writing – review & editing. WD: Conceptualization, Supervision, Writing – review & editing. MT: Software, Supervision, Writing – original draft. ND: Data curation, Investigation, Writing – review & editing. MM: Project administration, Software, Validation, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Acknowledgments
The authors would like to acknowledge the University of Gondar for reviewing and approving the ethical clearance for this study. We also extend our warmest gratitude to the data collectors, supervisors, study participants, and hospital directors for their invaluable cooperation and time.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
ASDs, Anti-Seizure Drugs; AOR, Adjusted Odds Ratio; CD, Cognitive Dysfunction; CI, Confidence Interval; COR, Crude Odds Ratio; CT, Computed Tomography; EEG, Electroencephalogram; IED, Interictal Epileptic Discharge; IQ, Intelligent Quotient; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; MRI, Magnetic Resonance Imaging; SD, Standard Deviation; TLE, Temporal Lobe Epilepsy.
References
1.
Eid T Gruenbaum SE Dhaher R Lee TSW Zhou Y Danbolt NC . The glutamate–glutamine cycle in epilepsy In: SchousboeASonnewaldU, editors. The glutamate/GABA-glutamine cycle. Cham: Springer International Publishing (2016). 351–400.
2.
Blume WT . The progression of epilepsy. Epilepsia. (2006) 47:71–8. doi: 10.1111/j.1528-1167.2006.00665.x
3.
Lenck-Santini PP Sakkaki S . Alterations of neuronal dynamics as a mechanism for cognitive impairment in epilepsy In: JonesNCKannerAM, editors. Psychiatric and behavioral aspects of epilepsy. Cham: Springer International Publishing (2020). 65–106.
4.
Gebre AK Haylay A . Sociodemographic, clinical variables, and quality of life in patients with epilepsy in Mekelle City, northern Ethiopia. Behav Neurol. (2018) 2018:1–6. doi: 10.1155/2018/7593573
5.
Zhu L Chen L Xu P Lu D Dai S Zhong L et al . Genetic and molecular basis of epilepsy-related cognitive dysfunction. Epilepsy Behav. (2020) 104:106848. doi: 10.1016/j.yebeh.2019.106848
6.
Muche EA Ayalew MB Abdela OA . Assessment of quality of life of epileptic patients in Ethiopia. Int J Chronic Dis. (2020) 2020:1–9. doi: 10.1155/2020/8714768
7.
Novak A Vizjak K Rakusa M . Cognitive impairment in people with epilepsy. J Clin Med. (2022) 11:267. doi: 10.3390/jcm11010267
8.
Sen A Capelli V Husain M . Cognition and dementia in older patients with epilepsy. Brain. (2018) 141:1592–608. doi: 10.1093/brain/awy022
9.
Kanner AM Helmstaedter C Sadat-Hossieny Z Meador K . Cognitive disorders in epilepsy I: clinical experience, real-world evidence and recommendations. Seizure. (2020) 83:216–22. doi: 10.1016/j.seizure.2020.10.009
10.
Baxendale S . Cognitive rehabilitation and prehabilitation in people with epilepsy. Epilepsy Behav. (2020) 106:107027. doi: 10.1016/j.yebeh.2020.107027
11.
Foster E Malpas CB Ye K Johnstone B Carney PW Velakoulis D et al . Antiepileptic drugs are not independently associated with cognitive dysfunction. Neurology. (2020) 94:e1051–61. doi: 10.1212/WNL.0000000000009061
12.
Power KN Gramstad A Gilhus NE Hufthammer KO Engelsen BA . Cognitive dysfunction after generalized tonic-clonic status epilepticus in adults. Acta Neurol Scand. (2018) 137:417–24. doi: 10.1111/ane.12898
13.
Dubey D Kothapalli N McKeon A Flanagan EP Lennon VA Klein CJ et al . Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. J Neuroimmunol. (2018) 323:62–72. doi: 10.1016/j.jneuroim.2018.07.009
14.
Huang H Cui G Tang H Kong L Wang X Cui C et al . Relationships between plasma expression levels of microRNA-146a and microRNA-132 in epileptic patients and their cognitive, mental and psychological disorders. Bioengineered. (2022) 13:941–9. doi: 10.1080/21655979.2021.2015528
15.
Vijayaraghavan L Natarajan S Krishnamoorthy ES . Peri-ictal and ictal cognitive dysfunction in epilepsy. Behav Neurol. (2011) 24:27–34. doi: 10.1155/2011/378649
16.
Laurent A Artiges E Mellerio C Boutin-Watine M Landré E Semah F et al . Metabolic correlates of cognitive impairment in mesial temporal lobe epilepsy. Epilepsy Behav. (2020) 105:106948. doi: 10.1016/j.yebeh.2020.106948
17.
Badawy RAB Johnson KA Cook MJ Harvey AS . A mechanistic appraisal of cognitive dysfunction in epilepsy. Neurosci Biobehav Rev. (2012) 36:1885–96. doi: 10.1016/j.neubiorev.2012.05.002
18.
Tekle-Haimanot R Forsgren L Ekstedt J . Incidence of epilepsy in rural Central Ethiopia. Epilepsia. (1997) 38:541–6. doi: 10.1111/j.1528-1157.1997.tb01138.x
19.
Almu S Tadesse Z Cooper P Hackett R . The prevalence of epilepsy in the Zay society, Ethiopia—An area of high prevalence. Seizure. (2006) 15:211–3. doi: 10.1016/j.seizure.2006.01.004
20.
Tadesse G Tinsae T Nakie G Rtbey G Andualem F Tadesse A et al . Prevalence and factors associated with depressive symptoms among patients with epilepsy in Ethiopia: a national-based systematic review and meta-analysis. Front Neurol. (2024) 15:1352648. doi: 10.3389/fneur.2024.1352648
21.
Biset G Woday A . Epilepsy treatment outcomes in the referral hospitals of Northeast Ethiopia. Epilepsy Res. (2021) 171:106584. doi: 10.1016/j.eplepsyres.2021.106584
22.
Sayed NM Aldin MTK Ali SE Hendi AE . Cognitive functions and epilepsy-related characteristics in patients with generalized tonic–clonic epilepsy: a cross-sectional study. Middle East Curr Psy. (2023) 30:15. doi: 10.1186/s43045-023-00293-6
23.
Shiferaw D Hailu E . Quality of life assessment among adult epileptic patients taking follow up Care at Jimma University Medical Center, Jimma, South West Ethiopia: using quality of life in epilepsy inventory- 31instrument. Global J Res Med Sci. (2018) 18:7–15.
24.
Estrella-Castillo DF Gómez-de-Regil L . Quality of life in Mexican patients with primary neurological or musculoskeletal disabilities. Disabil Health J. (2016) 9:127–33. doi: 10.1016/j.dhjo.2015.05.003
25.
Nau AL Mwape KE Wiefek J Schmidt K Abatih E Dorny P et al . Cognitive impairment and quality of life of people with epilepsy and neurocysticercosis in Zambia. Epilepsy Behav. (2018) 80:354–9. doi: 10.1016/j.yebeh.2017.10.042
26.
Minwuyelet F Mulugeta H Tsegaye D Lake B Getie A Tsegaye B et al . Quality of life and associated factors among patients with epilepsy at specialized hospitals, Northwest Ethiopia; 2019. PLoS One. (2022, 2022) 17:e0262814. doi: 10.1371/journal.pone.0262814
27.
Arinzechi EO Ogunrin OA Nwosu CM Nwani PO Enwereji KO Asomugha LA et al . A community-based case–control study of prevalence and pattern of cognitive impairments in patients with epilepsy residing in south-eastern Nigeria. J Neurosci Rural Pract. (2016) 7:405–11. doi: 10.4103/0976-3147.181488
28.
Gutter T Callenbach PMC Brouwer OF De Weerd AW . Prevalence of sleep disturbances in people with epilepsy and the impact on quality of life: a survey in secondary care. Seizure. (2019) 69:298–303. doi: 10.1016/j.seizure.2019.04.019
29.
Wazema DH Assefa ZM Shiferaw BZ Geleta OT Haile TG . Magnitude of cognitive impairment among patients with epilepsy at health institutions in Gurage zone, Ethiopia. SAGE Open Nurs. (2023) 9:23779608231154400. doi: 10.1177/23779608231154400
30.
Merkena MD . Prevalence of cognitive adverse outcomes in epileptic outpatients. J Neurol Stroke. (2016) 4:155. doi: 10.15406/jnsk.2016.04.00155
31.
Phabphal K Kanjanasatien J . Montreal cognitive assessment in cryptogenic epilepsy patients with normal Mini-mental state examination scores. Epileptic Disord. (2011) 13:375–81. doi: 10.1684/epd.2011.0469
32.
Dabilgou AA Dravé A Julie M Kyelem A Nana KA Napon C et al . Cognitive disorders in patients with epilepsy attending at neurology outpatient clinics. A multicenter prospective cross-sectional study from Burkina Faso- international journal of neurological disorders SCIRES literature. Int. J Neurol Disord. (2019) 3:20646. doi: 10.13140/RG.2.2.22239.20646
33.
Asnakew S Legas G Belete A Admasu FT Yitbarek GY Aytenew TM et al . Cognitive adverse effects of epilepsy and its predictors attending outpatient department of South Gondar zone hospitals, Amhara region, Ethiopia 2020 /2021. Plos One. (2021) 17:e0278908. doi: 10.1371/journal.pone.0278908
34.
Reyes A Kaestner E Edmonds EC Christina Macari A Wang ZI Drane DL et al . Diagnosing cognitive disorders in older adults with epilepsy. Epilepsia. (2021) 62:460–71. doi: 10.1111/epi.16780
35.
Vining EP . Cognitive dysfunction associated with antiepileptic drug therapy. Epilepsia. (1987) 28:S18–22. doi: 10.1111/j.1528-1157.1987.tb05767.x
36.
Abarrategui B Parejo-Carbonell B García García ME Di Capua D García-Morales I . The cognitive phenotype of idiopathic generalized epilepsy. Epilepsy Behav. (2018) 89:99–104. doi: 10.1016/j.yebeh.2018.10.007
37.
Jarčušková D Palušná M Gazda J Feketeová E Gdovinová Z . Which clinical and neuropsychological factors are responsible for cognitive impairment in patients with epilepsy?Int J Public Health. (2020) 65:947–56. doi: 10.1007/s00038-020-01401-7
38.
Kim J Park E An M . The cognitive impact of chronic diseases on functional capacity in community-dwelling adults. J Nurs Res. (2019) 27:e3:–e8. doi: 10.1097/jnr.0000000000000272
39.
Wang L Chen S Liu C Lin W Huang H . Factors for cognitive impairment in adult epileptic patients. Brain Behav. (2020) 10:e01475. doi: 10.1002/brb3.1475
40.
Lenck-Santini PP Scott RC . Mechanisms responsible for cognitive impairment in epilepsy. Cold Spring Harb Perspect Med. (2015) 5:a022772. doi: 10.1101/cshperspect.a022772
41.
Vlooswijk MC Jansen JF De Krom MC Majoie HM Hofman PA Backes WH et al . Functional MRI in chronic epilepsy: associations with cognitive impairment. Lancet Neurol. (2010) 9:1018–27. doi: 10.1016/S1474-4422(10)70180-0
42.
Khalife MR Scott RC Hernan AE . Mechanisms for cognitive impairment in epilepsy: moving beyond seizures. Front Neurol. (2022) 13:878991. doi: 10.3389/fneur.2022.878991
Summary
Keywords
cognitive dysfunction, associated factors, epilepsy, Ethiopia, MoCA
Citation
Maru L, Gela YY, Getnet M, Adugna DG, Anmut Bitew D, Tesfaye E, Aragie H, Behaile Teklemariam A, Debebe W, Taderegew MM, Dagnew Baye N and Melese M (2025) Cognitive dysfunction and its associated factors in patients with epilepsy at referral hospitals in the Amhara region: an institutional-based cross-sectional study. Front. Neurol. 16:1491716. doi: 10.3389/fneur.2025.1491716
Received
06 September 2024
Accepted
20 February 2025
Published
12 March 2025
Volume
16 - 2025
Edited by
Andrea Romigi, Saint Camillus International University of Health and Medical Sciences, Italy
Reviewed by
Ching Soong Khoo, National University of Malaysia, Malaysia
Anny Reyes, University of California, San Diego, United States
Updates
Copyright
© 2025 Maru, Gela, Getnet, Adugna, Anmut Bitew, Tesfaye, Aragie, Behaile Teklemariam, Debebe, Taderegew, Dagnew Baye and Melese.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lemlemu Maru, lemlemumaru300@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.